We create innovative treatments for nervous system damage due to injury or disease.
NervGen Pharma
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other traumatic and neurologic disorders
Phase 1b/2a CONNECT SCI Study of
NVG-291 in individuals living with spinal cord injury
NervGen is actively recruiting for a landmark Phase 1b/2a proof-of-concept clinical trial of
NVG-291 in individuals with spinal cord injury.
For information regarding recruitment, the call center phone number is +1 (855) 559-6902.
Stay Connected
Subscribe to our mailing list to stay up to date
The Latest
NEWS RELEASE
November 24, 2025
NervGen announced financial results and provided business updates for the third quarter ended September 30, 2025.
News Release
November 24, 2025
NervGen announced expanded CONNECT SCI Study data demonstrating unprecedented durable improvement in function, independence, and quality of life in individuals living with chronic SCI.
News Release
November 19, 2025
NervGen announced it has completed its previously announced non-brokered private placement to certain institutional investors and other accredited investors. The financing included participation from new and existing investors, including SCI Ventures and the Paul and Phyllis Fireman Charitable Foundation
